

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.

北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

ANNOUNCEMENT ON RESULTS OF SUBSIDIARY

Reference is made to the announcement (the “**Announcement**”) dated 28 October 2015 and published by Beijing Tong Ren Tang Chinese Medicine Company Limited (“**Tong Ren Tang Chinese Medicine**”), a subsidiary of Tong Ren Tang Technologies Co. Ltd. (the “**Company**”) and whose shares are listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (stock code: 8138), in relation to the third quarterly results of Tong Ren Tang Chinese Medicine and its subsidiaries for the nine months ended 30 September 2015.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following unaudited financial information of Tong Ren Tang Chinese Medicine and its subsidiaries for the nine months ended 30 September 2015 as set out in the Announcement.

CONDENSED CONSOLIDATED INCOME STATEMENT

	Unaudited	
	Nine months ended	
	30 September	
	2015	2014
	HK\$'000	HK\$'000
Revenue	715,370	537,265
Cost of sales	(222,341)	(157,575)
Gross profit	493,029	379,690
Distribution and selling expenses	(103,979)	(82,601)
General and administrative expenses	(61,633)	(48,227)
Other gains	1,343	1,474
Operating profit	328,760	250,336
Finance income	7,381	8,680
Finance costs	(862)	–
Share of (loss)/profit of investments accounted for using the equity method	(1,253)	(466)
Profit before income tax	334,026	258,550
Income tax expense	(62,976)	(44,450)
Profit for the period	271,050	214,100
Profit attributable to:		
Owners of the Company	257,224	207,327
Non-controlling interests	13,826	6,773
	271,050	214,100
Earnings per share attributable to owners of the Company (expressed in HK\$ per share)		
Basic and diluted	0.31	0.25

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Unaudited	
	Nine months ended	
	30 September	
	2015	2014
	HK\$'000	HK\$'000
Profit for the period	271,050	214,100
Other comprehensive income:		
<i>Item that may be subsequently reclassified to profit or loss</i>		
Currency translation differences	(18,133)	(3,367)
Total comprehensive income for the period	252,917	210,733
Attributable to:		
Owners of the Company	243,459	204,626
Non-controlling interests	9,458	6,107
	252,917	210,733

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Unaudited									
	Attributable to owners of the Company									
	Share capital HK\$'000	Share premium HK\$'000	Merger reserve HK\$'000	Other reserve HK\$'000	Statutory reserve HK\$'000	Exchange reserve HK\$'000	Retained earnings HK\$'000	Total HK\$'000	Non- controlling interests HK\$'000	Total equity HK\$'000
At 1 January 2014	415,000	452,363	(13,124)	742	1,634	6,141	410,959	1,273,715	36,004	1,309,719
Comprehensive income										
Profit for the period	-	-	-	-	-	-	207,327	207,327	6,773	214,100
Other comprehensive income										
Currency translation differences										
— the Group	-	-	-	-	-	(2,796)	-	(2,796)	(666)	(3,462)
— Joint ventures and an associate	-	-	-	-	-	95	-	95	-	95
Total comprehensive income	-	-	-	-	-	(2,701)	207,327	204,626	6,107	210,733
Transfer of retained earnings to statutory reserve	-	-	-	-	1,387	-	(1,387)	-	-	-
Transition to no-par value regime on 3 March 2014	452,363	(452,363)	-	-	-	-	-	-	-	-
Dividends relating to 2013	-	-	-	-	-	-	(66,400)	(66,400)	-	(66,400)
Capital injection to subsidiaries	-	-	-	-	-	-	-	-	11,041	11,041
Total transactions with owners, recognised directly in equity	452,363	(452,363)	-	-	1,387	-	(67,787)	(66,400)	11,041	(55,359)
At 30 September 2014	867,363	-	(13,124)	742	3,021	3,440	550,499	1,411,941	53,152	1,465,093
At 1 January 2015	867,363	-	(13,124)	742	2,927	(2,549)	630,390	1,485,749	51,112	1,536,861
Comprehensive income										
Profit for the period	-	-	-	-	-	-	257,224	257,224	13,826	271,050
Other comprehensive income										
Currency translation differences										
— the Group	-	-	-	-	-	(11,265)	-	(11,265)	(4,368)	(15,633)
— Joint ventures and an associate	-	-	-	-	-	(2,500)	-	(2,500)	-	(2,500)
Total comprehensive income	-	-	-	-	-	(13,765)	257,224	243,459	9,458	252,917
Transfer of retained earnings to statutory reserve	-	-	-	-	1,691	-	(1,691)	-	-	-
Dividends relating to 2014	-	-	-	-	-	-	(83,710)	(83,710)	-	(83,710)
Issue of new shares	71,426	-	-	-	-	-	-	71,426	-	71,426
Capital injection to subsidiaries	-	-	-	-	-	-	-	-	3,817	3,817
Total contributions by and distributions to owners of the Company, recognised directly in equity	71,426	-	-	-	1,691	-	(85,401)	(12,284)	3,817	(8,467)
Non-controlling interests arising from acquisition of a subsidiary	-	-	-	-	-	-	-	-	21,144	21,144
Change in ownership interest in a subsidiary without change of control	-	-	-	88	-	-	-	88	921	1,009
Total changes in ownership interests in subsidiaries that do not result in a loss of control	-	-	-	88	-	-	-	88	22,065	22,153
Total transactions with owners, recognised directly in equity	71,426	-	-	88	1,691	-	(85,401)	(12,196)	25,882	13,686
At 30 September 2015	938,789	-	(13,124)	830	4,618	(16,314)	802,213	1,717,012	86,452	1,803,464

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Gao Zhen Kun
Chairman of the Board

Beijing, the PRC
28 October 2015

As at the date of this announcement, the Board comprises Mr. Gao Zhen Kun, Mr. Gong Qin, Mr. Gu Hai Ou, Mr. Li Bin, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Miss Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.